Lipid profile during hormone replacement therapy: effect of different progestins?
Oral estrogens cause a decrease of low density lipoprotein cholesterol (LDL-chol.) and, especially an increase of high density lipoprotein cholesterol (HDL-chol.) levels, which both have potentially favorable effects; they also cause a triglyceride level increase, which probably has no clinical relevance except in cases with basal hypertriglyceridemia. Transdermal estradiol causes generally a minor decrease in LDL-chol. and minor increase HDL-chol. levels, with no increase or even decrease in triglyceride levels. The addition of androgenic progestins at conventionally used doses, while not interfering with LDL-chol. variations, causes a HDL-chol. decrease, which contrasts the effect of oral estrogens and completely reverses the effect of transdermal estradiol. On the contrary, the addition of a non androgenic progestin does not interfere with any of the estrogen induced lipid profile modifications.
Campagnoli
C
C
Servizio di Ginecologia Endocrinologica, Ospedale Ginecologico Sant'Anna, Torino, Italy.
Belforte
P
P
Di Sario
M M
MM
Lesca
L
L
D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D002979:Climacteric / Q000097:blood / Q000187:drug effects; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood*; D017270:Lipoprotein(a) / Q000097:blood; D045167:Progesterone Congeners / Q000008:administration & dosage / Q000009:adverse effects*; D014280:Triglycerides / Q000097:blood
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D008055:Lipids; D017270:Lipoprotein(a); D045167:Progesterone Congeners; D014280:Triglycerides